Monoclonal antibody for recognizing platelet membrane glycoprotein and application of monoclonal antibody in antithrombotic treatment

By developing monoclonal antibodies R813 and Y262 that recognize platelet membrane glycoproteins and forming a "cocktail" to completely block the function of platelet receptors, the problem that existing antiplatelet drugs are difficult to completely inhibit platelet aggregation is solved, and the effect of efficient platelet aggregation inhibition and low HAMA response is achieved.

CN119708233APending Publication Date: 2025-03-28FUJIAN HANHONG BIOTECHNOLOGY CO LTD
2 Cites 0 Cited by

Patent Information

Application Number
CN202510041700.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-01-10
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

Existing antiplatelet drugs can only block the platelet receptor GP IIb-IIIa from one perspective, making it difficult to completely inhibit platelet aggregation, and murine monoclonal antibodies have problems such as HAMA response in human applications.

Method used

Monoclonal antibodies R813 and Y262, which recognize platelet membrane glycoproteins, were developed, which acted on different sites of the platelet receptor GP IIIa and GP IIb-IIIa complex, respectively, to form a "cocktail" to completely block the function of platelet receptors, and the F(ab')2 fragment was prepared by enzymatic method to reduce molecular weight and HAMA reaction.

Benefits of technology

Complete inhibition of platelet aggregation has been achieved, the biological activity exceeds the existing antiplatelet drug Repro, and the dosage is small, which reduces the risk of HAMA response and platelet destruction and has huge antithrombotic therapy potential.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the field of human immunity, and particularly discloses a monoclonal antibody for recognizing platelet membrane glycoprotein and application of the monoclonal antibody in antithrombotic treatment. Monoclonal antibodies R813 and Y262 acting on different sites of a platelet receptor GP IIb-IIIa are developed, the monoclonal antibodies can well inhibit platelet aggregation, the two antibodies are combined to form the cocktail, the functions of the platelet receptor GP IIb-IIIa can be completely blocked, the platelet aggregation function is thoroughly inhibited, and the cocktail can be used for preparing the cocktail. The cocktail biological activity of the monoclonal antibody exceeds that of an antiplatelet drug Reopro, and the dosage is small; the antibody is prepared into an F (ab ') 2 fragment by an enzymolysis method, so that the molecular weight of the antibody is reduced while the biological activity is preserved, the amount of the antibody reaching an action target site is increased, the Fc terminal is removed, the HAMA reaction is reduced, and the platelet destruction caused by combination with a reticuloendothelial system is reduced. In addition, the enzymolysis method is simple to operate, low in cost and convenient for batch preparation and production of antibody fragments.
Need to check novelty before this filing date? Find Prior Art